50. 皮膚筋炎／多発性筋炎 ［臨床試験数：157，薬物数：207（DrugBank：76），標的遺伝子数：47，標的パスウェイ数：142］
Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-jRCTs031200005||30/04/2020||10/04/2020||Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis||Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis - ACDM||Dermatomyositis |
Collagen disease, inflammatory myopathy, cutaneous manifestation;D003882
|Oral administration of apremilast: Start with 10 mg of oral dose and gradually increase the dose until day 5, 30mg twice a day from day 6 (morning / evening) for a total of 12 weeks||Okiyama Naoko||NULL||Not Recruiting||>= 20age old||< 80age old||Both||5||Japan|
|2||NCT03529955||June 12, 2018||24/4/2018||Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis||A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis||Dermatomyositis, Adult Type||Drug: Apremilast 30mg||Tulane University||NULL||Recruiting||18 Years||75 Years||All||10||Phase 2||United States|
|3||NCT01140503||February 2010||6/4/2010||A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis||An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis||Dermatomyositis||Drug: Apremilast||Stanford University||NULL||Terminated||18 Years||N/A||All||5||N/A||United States|